keyword
MENU ▼
Read by QxMD icon Read
search

gastrointestinal cancers

keyword
https://www.readbyqxmd.com/read/28335396/optimization-of-conditions-for-cyanidin-3-oglucoside-c3g-nanoliposome-production-by-response-surface-methodology-and-cellular-uptake-studies-in-caco-2-cells
#1
Tisong Liang, Rongfa Guan, Haitao Shen, Qile Xia, Mingqi Liu
We aimed to optimize the formulation of C3G nanoliposomes using response surface methodology. Additionally, we evaluated the stability, particle change, and encapsulation efficiency (EE) of C3G nanoliposomes under different temperatures and storage durations, as well as in simulated gastrointestinal juice (SGF) and simulated intestinal fluid. The morphology of C3G nanoliposomes was observed by transmission electron microscope. The ability of C3G nanoliposomes to affect cancer cell morphology and inhibit cancer cell proliferation was studied with Caco-2 cells...
March 13, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28334729/slug-transcription-factor-a-pro-survival-and-prognostic-factor-in-gastrointestinal-stromal-tumour
#2
Olli-Pekka Pulkka, Bengt Nilsson, Maarit Sarlomo-Rikala, Peter Reichardt, Mikael Eriksson, Kirsten Sundby Hall, Eva Wardelmann, Aki Vehtari, Heikki Joensuu, Harri Sihto
BACKGROUND: The SLUG transcription factor has been linked with the KIT signalling pathway that is important for gastrointestinal stromal tumour (GIST) tumourigenesis. Its clinical significance in GIST is unknown. METHODS: Influence of SLUG expression on cell proliferation and viability were investigated in GIST48 and GIST882 cell lines. The association between tumour SLUG expression in immunohistochemistry and recurrence-free survival (RFS) was studied in two clinical GIST series, one with 187 patients treated with surgery alone, and another one with 313 patients treated with surgery and adjuvant imatinib...
March 23, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28333867/determining-risk-of-severe-gastrointestinal-toxicity-based-on-pretreatment-gut-microbial-community-in-patients-receiving-cancer-treatment-a-new-predictive-strategy-in-the-quest-for-personalized-cancer-medicine
#3
Hannah R Wardill, Wim J E Tissing
PURPOSE OF REVIEW: Currently, our ability to accurately predict a patient's risk of developing severe gastrointestinal toxicity from their cancer treatment is limited. Risk stratification continues to rely on traditional patient-related and treatment-related factors including age, ethnicity, sex, comorbidities, genetics, agent, dose and schedule. Although informative, these crude measures continue to underestimate toxicity risk, and hence alternative methods of risk prediction must be investigated...
March 22, 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28333866/prevention-of-gastrointestinal-side-effects-in-paediatric-oncology-what-are-the-guidelines
#4
Karis K F Cheng
PURPOSE OF REVIEW: Gastrointestinal side-effects, particularly with regard to alimentary tract mucositis and chemotherapy-induced nausea and vomiting (CINV), continue to be frequent and debilitating symptomatic conditions among children and adolescents receiving cytotoxic cancer therapy. Further avenues of progress for mucositis and CINV prevention in paediatric oncology setting are warranted. RECENT FINDINGS: The current article reviews the major guidelines and literature published in 2016 pertaining to the prevention of mucositis and CINV...
March 22, 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28333199/effect-of-butyrate-and-lactobacillus-gg-on-a-butyrate-receptor-and-transporter-during-campylobacter-jejuni-exposure
#5
Gail A M Cresci, Paul C Mayer, Stuart A Thompson
Campylobacter jejuni (C. jejuni) frequently infects humans causing many gastrointestinal symptoms, fever, fatigue and several long-term debilitating diseases. Current treatment for campylobacteriosis includes rehydration and in some cases, antibiotic therapy. Probiotics are used to treat several gastrointestinal diseases. Butyrate is a short-chain fatty acid known to promote intestinal health. Interaction of butyrate with its respective receptor (HCAR2) and transporter (SLC5A8), both expressed in the intestine, is associated with water and electrolyte absorption as well as providing defense against colon cancer and inflammation...
February 23, 2017: FEMS Microbiology Letters
https://www.readbyqxmd.com/read/28333072/detection-of-circulating-tumor-cells-using-negative-enrichment-immunofluorescence-and-an-in-situ-hybridization-system-in-pancreatic-cancer
#6
Yu Xu, Tai Qin, Jing Li, Xiuchao Wang, Chuntao Gao, Chao Xu, Jihui Hao, Jingcheng Liu, Song Gao, He Ren
Pancreatic cancer (PC) is the most lethal type of gastrointestinal cancer, and early detection and monitoring is an urgent problem. Circulating tumor cells (CTCs) are emerging as a non-invasive biomarker for tumor detection. However, the low sensitivity is a main problem in the traditional CellSearch System for detecting CTCs, especially in patients with PC. In this study, we used negative enrichment (NE), immunofluorescence and in situ hybridization (FISH) of chromosome 8 (NE-iFISH) to capture and identify CTCs in PC patients...
March 23, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28333021/a-phase-1-2-trial-of-a-combination-of-paclitaxel-and-trastuzumab-with-daily-irradiation-or-paclitaxel-alone-with-daily-irradiation-after-transurethral-surgery-for-noncystectomy-candidates-with-muscle-invasive-bladder-cancer-trial-nrg-oncology-rtog-0524
#7
M Dror Michaelson, Chen Hu, Huong T Pham, Douglas M Dahl, Chin Lee-Wu, Gregory P Swanson, Jacqueline Vuky, R Jeffrey Lee, Luis Souhami, Brian Chang, Asha George, Howard Sandler, William Shipley
PURPOSE: Bladder preservation therapy is an effective treatment for muscle-invasive urothelial carcinoma (UC). In this study we treated noncystectomy candidates with daily radiation and weekly paclitaxel for 7 weeks. Patients whose tumors showed her2/neu overexpression were additionally treated with weekly trastuzumab. METHODS AND MATERIALS: Sixty-eight evaluable patients were treated with radiation therapy and either paclitaxel + trastuzumab (group 1) or paclitaxel alone (group 2)...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28333019/a-comparison-between-low-dose-rate-brachytherapy-with-or-without-androgen-deprivation-external-beam-radiation-therapy-with-or-without-androgen-deprivation-and-radical-prostatectomy-with-or-without-adjuvant-or-salvage-radiation-therapy-for-high-risk-prostate
#8
Jay P Ciezki, Michael Weller, Chandana A Reddy, Jeffrey Kittel, Harguneet Singh, Rahul Tendulkar, Kevin L Stephans, James Ulchaker, Kenneth Angermeier, Andrew Stephenson, Steven Campbell, Georges-Pascal Haber, Eric A Klein
PURPOSE: We compare the efficacy and toxicity among the 3 major modalities available used to treat high-risk prostate cancer (HRCaP). METHODS AND MATERIALS: From 1996 to 2012, 2557 HRCaP patients were treated: 734 received external beam radiation therapy (EBRT) with or without androgen deprivation therapy (ADT), 515 received low-dose-rate prostate brachytherapy (LDR) with or without ADT, and 1308 received radical prostatectomy (RP) with or without EBRT. Biochemical relapse-free survival (bRFS), clinical relapse-free survival (cRFS), and prostate cancer-specific mortality (PCSM) were assessed...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28333018/nationwide-multicenter-retrospective-study-on-high-dose-rate-brachytherapy-as-monotherapy-for-prostate-cancer
#9
Yasuo Yoshioka, Tadayuki Kotsuma, Akira Komiya, Shinji Kariya, Koji Konishi, Norio Nonomura, Kazuhiko Ogawa, Eiichi Tanaka, Kensaku Nishimura, Yasuyoshi Fujiuchi, Hiroshi Kitamura, Takuji Yamagami, Ichiro Yamasaki, Kazuo Nishimura, Teruki Teshima, Katsumasa Nakamura, Jun Itami
PURPOSE: To present, analyze, and discuss results of a nationwide, multicenter, retrospective study on high-dose-rate brachytherapy (HDR-BT) as monotherapy for low-, intermediate-, and high-risk prostate cancer. METHODS AND MATERIALS: From 1995 through 2013, 524 patients, 73 (14%) with low-risk, 207 (40%) with intermediate-risk, and 244 (47%) with high-risk prostate cancer, were treated with HDR-BT as monotherapy at 5 institutions in Japan. Dose fractionations were 27 Gy/2 fractions for 69 patients (13%), 45...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28333014/single-nucleotide-polymorphism-tgf%C3%AE-1-r25p-correlates-with-acute-toxicity-during-neoadjuvant-chemoradiotherapy-in-rectal-cancer-patients
#10
J Joshua Smith, Isaac Wasserman, Sarah A Milgrom, Oliver S Chow, Chin-Tung Chen, Sujata Patil, Karyn A Goodman, Julio Garcia-Aguilar
PURPOSE: To validate the finding of an association between single nucleotide polymorphisms (SNPs) and toxicity during chemoradiotherapy (CRT) in rectal cancer patients, in an independent population. METHODS AND MATERIALS: The cohort consisted of 165 patients who received CRT for rectal cancer from 2006 to 2012. Prospectively recorded toxicity information, graded according to the Common Terminology Criteria for Adverse Events version 3.0, was retrieved from the medical record...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28332990/continuous-activity-monitoring-during-concurrent-chemoradiotherapy
#11
Nitin Ohri, Rafi Kabarriti, William R Bodner, Keyur J Mehta, Viswanathan Shankar, Balazs Halmos, Missak Haigentz, Bruce Rapkin, Chandan Guha, Shalom Kalnicki, Madhur Garg
PURPOSE: To perform a prospective trial testing the feasibility and utility of acquiring activity data as a measure of health status during concurrent chemoradiotherapy. METHODS AND MATERIALS: Ambulatory patients who were planned for treatment with concurrent chemoradiotherapy with curative intent for cancers of the head and neck, lung, or gastrointestinal tract were provided with activity monitors before treatment initiation. Patients were asked to wear the devices continuously throughout the radiation therapy course...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28332353/port-site-metastases-and-chimney-effect-of-b-ultrasound-guided-and-laparoscopically-assisted-hyperthermic-intraperitoneal-perfusion-chemotherapy
#12
Ming Chen Ba, Hui Long, Xiang Liang Zhang, Yuan Feng Gong, Zhao Fei Yan, Shuai Wang, Yun Qiang Tang, Shu Zhong Cui
PURPOSE: CO₂ leakage along the trocar (chimney effect) has been proposed to be an important factor underlying port-site metastasis after laparoscopic surgery. This study aimed to test this hypothesis by comparing the incidence of port-site metastasis between B-ultrasound-guided and laparoscopically-assisted hyperthermic intraperitoneal perfusion chemotherapy (HIPPC). MATERIALS AND METHODS: Sixty-two patients with malignant ascites induced by gastrointestinal or ovarian cancer were divided into two groups to receive either B-ultrasound-guided or laparoscopically-assisted HIPPC...
May 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/28330549/-hyperthermic-intraperitoneal-chemotherapy-at-the-primary-gastrointestinal-cancer-operation
#13
Thea Helene Degett, Hans-Christian Pommergaard, Ismail Gögenur
Up to 20% of the patients who undergo radical surgery for colorectal cancer experience recurrence. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have shown to be effective treatment of peritoneal carcinomatosis. HIPEC administered at the primary operation in high-risk patients may also be effective in preventing peritoneal carcinomatosis and improve survival in patients with advanced gastrointestinal cancer.
March 20, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/28329738/transarterial-chemo-embolization-for-liver-metastases-in-patients-with-neuroendocrine-tumors
#14
Hiroyuki Okuyama, Masafumi Ikeda, Hideaki Takahashi, Izumi Ohno, Yusuke Hashimoto, Shuichi Mitsunaga, Yasunari Sakamoto, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Tatsushi Kobayashi, Yasuaki Arai, Takuji Okusaka
OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of transarterial (chemo)embolization [TA(C)E] for the control of liver metastasis in patients with neuroendocrine tumors (NETs). METHODS: In this retrospective study, we enrolled 43 patients with metastatic NETs who had been treated with TA(C)E between December 1999 and June 2013 at the National Cancer Center Hospital, Tokyo or the National Cancer Center Hospital East, Kashiwa. We assessed tumor response, time to treatment failure (TTF), overall survival (OS), and frequency of adverse events in these patients, and attempted to identify predictors of TTF...
March 23, 2017: Oncology
https://www.readbyqxmd.com/read/28327934/pazopanib-or-placebo-in-completely-resected-stage-i-nsclc-patients-results-of-the-phase-ii-ifct-0703-trial
#15
B Besse, J Mazières, L Ribassin-Majed, F Barlesi, J Bennouna, R Gervais, L Moreau, H Berard, D Debieuvre, O Molinier, D Moro-Sibilot, P J Souquet, S Jacquot, L Petit, H Lena, J P Pignon, B Lacas, F Morin, B Milleron, G Zalcman, J C Soria
Background: Adjuvant treatment in resected stage I non-small cell lung cancer (NSCLC) is generally not recommended. Pazopanib is an oral tyrosine kinase inhibitor of VEGFR-1/2/3 and PDGFR-α/β. We explored the feasibility and efficacy of adjuvant pazopanib in this population. Patients and methods: In this double-blind phase II/III trial, patients with resected stage I NSCLC were randomized to placebo or pazopanib 800 mg/d (P800) for 6 months with a two-step Fleming design...
February 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327275/a-population-based-study-of-outcomes-in-patients-with-gastrointestinal-neuroendocrine-tumours
#16
Todd McMullen, Akram Al-Jahdali, Christopher de Gara, Sunita Ghosh, Alexander McEwan, Daniel Schiller
BACKGROUND: Neuroendocrine tumours (NETs) are heterogeneous, with varying presentations and treatment options. To our knowledge, there are no randomized and few long-term studies of patient outcomes. The role of surgical and medical therapy for local, regional and metastatic disease continues to be evaluated in the literature. METHODS: We conducted a population-based search of the provincial cancer registry to identify patients with gastrointestinal NETs from the stomach, small intestine, colon and rectum diagnosed between 1990 and 2005 and assessed their outcomes...
April 1, 2017: Canadian Journal of Surgery. Journal Canadien de Chirurgie
https://www.readbyqxmd.com/read/28325058/-mixed-adenoneuroendocrine-carcinoma-manec-of-the-gastrointestinal-tract
#17
R Šefr, L Němec, P Fabian, L Fiala
Mixed adenoneuroendocrine carcinoma (MANEC) is a rare tumour of the gastrointestinal tract composed of adenocarcinoma and neuroendocrine carcinoma. This pathologic diagnosis was recently defined by the WHO in 2010. The tumour may appear in various levels of the digestive tract including the oesophagus, stomach, colon and appendix. Biological behaviour of MANEC seems to be quite unpredictable and the prognosis uncertain. The disease may also mimic "simple" carcinoma. Only several tens of cases have been reported so far...
2017: Rozhledy V Chirurgii: Měsíčník Československé Chirurgické Společnosti
https://www.readbyqxmd.com/read/28324922/the-clinical-significance-of-occult-gastrointestinal-primary-tumours-in-metastatic-cancer-a-population-retrospective-cohort-study
#18
Malek B Hannouf, Eric Winquist, Salaheddin M Mahmud, Muriel Brackstone, Sisira Sarma, George Rodrigues, Peter K Rogan, Jeffrey S Hoch, Gregory S Zaric
Purpose: To estimate the incidence of occult gastrointestinal (GI) primary tumours in patients with metastatic cancer of uncertain primary origin and evaluate their influence on treatments and overall survival (OS). Materials and Methods: We used population heath data from Manitoba, Canada to identify all patients initially diagnosed with metastatic cancer between 2002 and 2011. We defined patients to have "occult" primary tumour if the primary was found at least 6 months after initial diagnosis...
March 21, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28324283/prognostic-value-of-computed-tomography-measured-parameters-of-body-composition-in-primary-operable-gastrointestinal-cancers
#19
Douglas Black, Craig Mackay, George Ramsay, Zaid Hamoodi, Shayanthan Nanthakumaran, Kenneth G M Park, Malcolm A Loudon, Colin H Richards
BACKGROUND: Previous reports suggest that body composition parameters can be used to predict outcomes for patients with gastrointestinal (GI) cancers. However, evidence for an association with long-term survival is conflicting, with much of the data derived from patients with advanced disease. This study examined the effect of body composition on survival in primary operable GI cancer. METHODS: Patients with resectable adenocarcinoma of the GI tract (esophagus, stomach, colon, rectum) between 2006 and 2014 were identified from a prospective database...
March 21, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28323577/mitigation-of-radiation-induced-epithelial-damage-by-the-tlr5-agonist-entolimod-in-a-mouse-model-of-fractionated-head-and-neck-irradiation
#20
Ilia A Toshkov, Anatoli S Gleiberman, Vadim L Mett, Alan D Hutson, Anurag K Singh, Andrei V Gudkov, Lyudmila G Burdelya
Radiation treatment of head and neck cancer frequently causes severe collateral damage to normal tissues including mouth mucosa, salivary glands and skin. This toxicity limits the radiation dose that can be delivered and affects the patient's quality of life. Previous studies in mice and nonhuman primates showed that entolimod, a toll-like receptor 5 (TLR5) agonist derived from bacterial flagellin, effectively reduced radiation damage to hematopoietic and gastrointestinal tissues in both total-body and local irradiation scenarios, with no protection of tumors...
March 21, 2017: Radiation Research
keyword
keyword
117572
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"